Novartis Launches CAROLEEN Observational Study to Validate Real-World Efficacy of Kisqali in Breast Cancer Treatment
Purpose and Background of the CAROLEEN Observational Study
Novartis is initiating CAROLEEN (NCT06830720), a large-scale observational study, to evaluate the real-world clinical efficacy of Kisqali (ribociclib), its CDK4/6 inhibitor, in combination with an aromatase inhibitor (AI). This study aims to gather real-world evidence (RWE) on the drug's effectiveness and safety profile beyond the controlled environment of clinical trials. Specifically, it follows the FDA approval on September 17, 2024, for Kisqali as adjuvant treatment for HR+/HER2- Stage II and III early breast cancer (eBC) to prevent recurrence. Novartis intends to build a database of real-world data (RWD) to expand the drug's prescription base and enhance confidence in its use.
Patient Selection and Comparative Analysis Strategy
The study will involve a long-term follow-up of approximately 3,250 patients with high-risk, hormone receptor-positive, and HER2-negative (HR+/HER2-) early breast cancer. A key aspect of the study is the collection and comparison of data from patients receiving Verzenio (abemaciclib), a competing drug from Eli Lilly, in combination with endocrine therapy (ET). This is a strategic design intended to objectively demonstrate Kisqali's advantages over competing drugs in terms of patient compliance and quality of life (QoL). By analyzing patients' actual treatment experiences from various angles, Novartis aims to secure marketing points beyond simple survival rate improvements.
Clinical Data and Market Competition
The CAROLEEN observational study focuses on replicating the positive results of the NATALEE Phase 3 clinical trial, which served as the basis for the FDA approval. In the NATALEE trial, Kisqali demonstrated significant efficacy with a hazard ratio (HR) of 0.716 for invasive disease-free survival (iDFS) and a p-value of less than 0.0001 after 5 years of follow-up. However, with Verzenio expected to generate global sales of $5.7 billion in 2025 and already holding a leading position in the market, Kisqali, as a later entrant, needs to quickly demonstrate its real-world strengths. Kisqali is rapidly gaining ground with annual sales of $4.78 billion in 2025, and this study is expected to provide a powerful tool to reshape the market.
Basis for Clinical Guidelines and Expanded Prescriptions
The data generated from the CAROLEEN study will serve as strong evidence in future global clinical guidelines and national health insurance coverage reviews. By accumulating data on the drug's tolerability and management of side effects in real-world patients, the study will provide healthcare professionals with practical guidance for making prescription decisions. In the long term, this will help to encourage government and private insurers to expand coverage, thereby maximizing Kisqali's market penetration. Novartis's upward revision of Kisqali's peak sales guidance to at least $10 billion is supported by this comprehensive strategy to establish real-world evidence.
The CAROLEEN observational study is a critical market share defense and expansion strategy for Novartis, a late entrant in the global CDK4/6 inhibitor market, which is expected to reach approximately $14.6 billion in 2025, to surpass its competitor, Eli Lilly's Verzenio. By re-validating the clinical superiority demonstrated in the NATALEE Phase 3 trial, with an iDFS hazard ratio of 0.716 (p-value < 0.0001), in a real-world setting, the early establishment of real-world data for long-term prescription acquisition will determine short-term marketing success. From a clinical researcher's perspective, the accumulation of direct quality of life (QoL) and compliance comparison data with the Verzenio treatment group included as a control will serve as a catalyst for establishing more refined, individualized adjuvant therapy guidelines. Given that Novartis has upwardly revised Kisqali's peak sales guidance to over $10 billion, the data from this study, scheduled to be completed in 2030, will form the basis for securing priority in global health insurance coverage and strengthening its dominant market position in the long term. As a result, it is expected to demonstrate overwhelming clinical benefits compared to the existing standard treatment of aromatase inhibitor monotherapy in the early breast cancer treatment market, leading to a complete generational shift in prescription guidelines.
Source: ClinicalTrials.gov (api_ct)